|
1
|
Pabst O, Cerovic V and Hornef M: Secretory
IgA in the coordination of establishment and maintenance of the
microbiota. Trends Immunol. 37:287–296. 2016.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Lycke NY and Bemark M: The regulation of
gut mucosal IgA B-cell responses: Recent developments. Mucosal
Immunol. 10:1361–1374. 2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Takeuchi T, Miyauchi E, Kanaya T, Kato T,
Nakanishi Y, Watanabe T, Kitami T, Taida T, Sasaki T, Negishi H, et
al: Acetate differentially regulates IgA reactivity to commensal
bacteria. Nature. 595:560–564. 2021.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Inamine T and Schnabl B: Immunoglobulin A
and liver diseases. J Gastroenterol. 53:691–700. 2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Doi H, Hayashi E, Arai J, Tojo M, Morikawa
K, Eguchi J, Ito T, Kanto T, Kaplan DE and Yoshida H: Enhanced
B-cell differentiation driven by advanced cirrhosis resulting in
hyperglobulinemia. J Gastroenterol Hepatol. 2018.PubMed/NCBI View Article : Google Scholar : (Online ahead of
print).
|
|
6
|
Kotsiliti E, Leone V, Schuehle S, Govaere
O, Li H, Wolf MJ, Horvatic H, Bierwirth S, Hundertmark J, Inverso
D, et al: Intestinal B-cells license metabolic T-cell activation in
NASH microbiota/antigen-independently and contribute to fibrosis by
IgA-FcR signalling. J Hepatol. 79:296–313. 2023.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Tomita K, Teratani T, Yokoyama H, Suzuki
T, Irie R, Ebinuma H, Saito H, Hokari R, Miura S and Hibi T: Serum
immunoglobulin A concentration is an independent predictor of liver
fibrosis in nonalcoholic steatohepatitis before the cirrhotic
stage. Dig Dis Sci. 56:3648–3654. 2011.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Maleki I, Aminafshari MR, Taghvaei T,
Hosseini V, Rafiei A, Torabizadeh Z, Barzin M and Orang E: Serum
immunoglobulin A concentration is a reliable biomarker for liver
fibrosis in non-alcoholic fatty liver. World J Gastroenterol.
20:12566–12573. 2014.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Danpanichkul P, Ng CH, Muthiah MD,
Duangsonk K, Yong JN, Tan DJH, Lim WH, Wong ZY, Syn N, Tsusumi T,
et al: The silent burden of non-alcoholic fatty liver disease in
the elderly : A global burden of disease analysis. Aliment
Pharmacol Ther. 58:1062–1074. 2023.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Devarbhavi H, Asrani SK, Arab JP, Nartey
YA, Pose E and Kamath PS: Global burden of liver disease: 2023
update. J Hepatol. 79:516–537. 2023.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Younossi ZM, Henry L, Isaacs S and Cusi K:
Identification of high risk NAFLD patients in endocrinology
clinics. Endocr Pract. 29:912–918. 2023.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Wattacheril JJ, Abdelmalek MF, Lim JK and
Sanyal AJ: AGA clinical practice update on the role of noninvasive
biomarkers in the evaluation and management of nonalcoholic fatty
liver disease: Expert review. Gastroenterology. 165:1080–1088.
2023.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Eddowes PJ, Sasso M, Allison M, Tsochatzis
E, Anstee QM, Sheridan D, Guha IN, Cobbold JF, Deeks JJ, Paradis V,
et al: Accuracy of FibroScan controlled attenuation parameter and
liver stiffness measurement in assessing steatosis and fibrosis in
patients with nonalcoholic fatty liver disease. Gastroenterology.
156:1717–1730. 2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Kiyoaki I, Sumida Y, Nakade Y, Okumura A,
Nishimura S, Ibusuki M, Kitano R, Sakamoto K, Kimoto S, Inoue T, et
al: Mac-2 binding protein glycosylation isomer, the FIB-4 index,
and a combination of the two as predictors of non-alcoholic
steatohepatitis. PLoS One. 17(e0277380)2022.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Guo J, Han X, Huang W, You Y and Jicheng
Z: Interaction between IgA and gut microbiota and its role in
controlling metabolic syndrome. Obes Rev. 22(e13155)2021.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Guo X, Meng G, Liu F, Zhang Q, Liu L, Wu
H, Du H, Shi H, Xia Y, Liu X, et al: Serum levels of
immunoglobulins in an adult population and their relationship with
type 2 diabetes. Diabetes Res Clin Pract. 115:76–82.
2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Rafaqat S, Sattar A, Khalid A and Rafaqat
S: Role of liver parameters in diabetes mellitus-a narrative
review. Endocr Regul. 57:200–220. 2023.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Kim EH, Kim HK, Lee MJ, Bae SJ, Choe J,
Jung CH, Kim CH, Park JY and Lee WJ: Sex differences of visceral
fat area and visceral-to-subcutaneous fat ratio for the risk of
incident type 2 diabetes mellitus. Diabetes Metab J. 46:486–498.
2022.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Mitsiopoulos N, Baumgartner RN, Heymsfield
SB, Lyons W, Gallagher D and Ross R: Cadaver validation of skeletal
muscle measurement by magnetic resonance imaging and computerized
tomography. J Appl Physiol (1985). 85:115–122. 1998.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Rinella ME, Lazarus JV, Ratziu V, Francque
SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab
JP, et al: A multisociety Delphi consensus statement on new fatty
liver disease nomenclature. J Hepatol. 79:1542–1556.
2023.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Fujiwara N, Nakagawa H, Kudo Y, Tateishi
R, Taguri M, Watadani T, Nakagomi R, Kondo M, Nakatsuka T, Minami
T, et al: Sarcopenia, intramuscular fat deposition, and visceral
adiposity independently predict the outcomes of hepatocellular
carcinoma. J Hepatol. 63:131–140. 2015.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Shephard DA: The 1975 declaration of
helsinki and consent. Can Med Assoc J. 115:1191–1192.
1976.PubMed/NCBI
|
|
23
|
Tarantino G, Citro V, Esposit P, Giaquinto
S, de Leone A, Milan G, Tripodi FS, Cirillo M and Lobello R: Blood
ammonia levels in liver cirrhosis: A clue for the presence of
portosystemic collateral veins. BMC Gastroenterol.
9(21)2009.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Johnson PJ, Berhane S, Kagebayashi C,
Satomura S, Teng M, Reeves HL, O'Beirne J, Fox R, Skowronska A,
Palmer D, et al: Assessment of liver function in patients with
hepatocellular carcinoma: A new evidence-based approach-the ALBI
grade. J Clin Oncol. 33:550–558. 2015.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Kamath P, Wiesner RH, Malinchoc M, Kremers
W, Therneau TM, Kosberg CL, D'Amico G, Dickson ER and Kim WR: A
model to predict survival in patients with end-stage liver disease.
Hepatology. 33:464–470. 2001.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Vallet-Pichard A, Mallet V, Nalpas B,
Verkarre V, Nalpas A, Dhalluin-Venier V, Fontaine H and Pol S:
FIB-4: An inexpensive and accurate marker of fibrosis in HCV
infection. Comparison with liver biopsy and FibroTest. Hepatology.
46:32–36. 2007.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Newsome PN, Sasso M, Deeks JJ, Paredes A,
Boursier J, Chan WK, Yilmaz Y, Czernichow S, Zheng MH, Wong VW, et
al: FibroScan-AST (FAST) score for the non-invasive identification
of patients with non-alcoholic steatohepatitis with significant
activity and fibrosis: A prospective derivation and global
validation study. Lancet Gastroenterol Hepatol. 5:362–373.
2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Mózes FE, Lee JA, Vali Y, Alzoubi O,
Staufer K, Trauner M, Paternostro R, Stauber RE, Holleboom AG, van
Dijk AM, et al: Performance of non-invasive tests and histology for
the prediction of clinical outcomes in patients with non-alcoholic
fatty liver disease: An individual participant data meta-analysis.
Lancet Gastroenterol Hepatol. 8:704–713. 2023.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Torruellas C, French SW and Medici V:
Diagnosis of alcoholic liver disease. World J Gastroenterol.
20:11684–11699. 2014.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Zagato E, Mazzini E and Rescigno M: The
variegated aspects of immunoglobulin A. Immunol Lett. 178:45–49.
2016.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Tarantino G and Citro V: What are the
common downstream molecular events between alcoholic and
nonalcoholic fatty liver? Lipids Health Dis. 23(41)2024.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Jung CH, Rhee EJ, Kwon H, Chang Y, Ryu S
and Lee WY: Visceral-to-subcutaneous abdominal fat ratio is
associated with nonalcoholic fatty liver disease and liver
fibrosis. Endocrinol Metab (Seoul). 35:165–176. 2020.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Hernández-Conde M, Llop E, Carrillo CF,
Tormo B, Abad J, Rodriguez L, Perelló C, Gomez ML, Martínez-Porras
JL, Puga NF, et al: Estimation of visceral fat is useful for the
diagnosis of significant fibrosis in patients with non-alcoholic
fatty liver disease. World J Gastroenterol. 26:6514–6705.
2020.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Ha NB, Cho SJ, Mohamad Y, Kent D, Jun G,
Wong R, Swarnakar V, Lin S, Maher JJ and Lai JC: Visceral adipose
tissue inflammation and radiographic visceral-to-subcutaneous
adipose tissue ratio in patients with cirrhosis. Dig Dis Sci.
67:3436–3444. 2022.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Tarantino G, Sinatti G, Citro V, Santini
SJ and Balsano C: Sarcopenia, a condition shared by various
diseases: Can we alleviate or delay the progression? Intern Emerg
Med. 18:1887–1895. 2023.PubMed/NCBI View Article : Google Scholar
|
